India, May 22 -- Agios Pharmaceuticals, Inc. (AGIO) announced that the European Commission has approved PYRUKYND for adults with alpha- or beta-thalassemia, marking the first and only medicine authorized across all EU member states for both transfusion-dependent and non-transfusion-dependent forms of the disease.
Thalassemia is a rare inherited blood disorder that reduces the body's ability to produce healthy red blood cells, often leading to chronic anemia, fatigue, and the need for lifelong blood transfusions. Treatment options have historically been limited, especially for adults who require frequent transfusions.
PYRUKYND (mitapivat) is an oral activator of pyruvate kinase, an enzyme that helps red blood cells produce energy. By impro...